Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00639769 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00639769 is a Phase 2 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 41 participants.
The verdict
NCT00639769, a Phase 2 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: To determine if CPT-11 given together with cisplatin is effective in treating recurrent or metastatic head and neck cancer.
Interventions
- DRUG cisplatin
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2002-02 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00639769
The ClinicalTrials.gov registry entry for NCT00639769 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00639769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00639769 about?
NCT00639769 is a clinical study titled "Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: To determine if ...
What is the current status of trial NCT00639769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2002-02. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00639769?
The interventions under investigation include: cisplatin (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00639769?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.